International Journal of Cell Biology

International Journal of Cell Biology / 2015 / Article
Special Issue

Advances in Hyaluronan Biology: Signaling, Regulation, and Disease Mechanisms

View this Special Issue

Review Article | Open Access

Volume 2015 |Article ID 208303 |

Manuela Viola, Evgenia Karousou, Maria Luisa D’Angelo, Ilaria Caon, Giancarlo De Luca, Alberto Passi, Davide Vigetti, "Regulated Hyaluronan Synthesis by Vascular Cells", International Journal of Cell Biology, vol. 2015, Article ID 208303, 8 pages, 2015.

Regulated Hyaluronan Synthesis by Vascular Cells

Academic Editor: Paul H. Weigel
Received23 Oct 2014
Accepted27 Jan 2015
Published10 Sep 2015


Cellular microenvironment plays a critical role in several pathologies including atherosclerosis. Hyaluronan (HA) content often reflects the progression of this disease in promoting vessel thickening and cell migration. HA synthesis is regulated by several factors, including the phosphorylation of HA synthase 2 (HAS2) and other covalent modifications including ubiquitination and O-GlcNAcylation. Substrate availability is important in HA synthesis control. Specific drugs reducing the UDP precursors are able to reduce HA synthesis whereas the hexosamine biosynthetic pathway (HBP) increases the concentration of HA precursor UDP-N-acetylglucosamine (UDP-GlcNAc) leading to an increase of HA synthesis. The flux through the HBP in the regulation of HA biosynthesis in human aortic vascular smooth muscle cells (VSMCs) was reported as a critical aspect. In fact, inhibiting O-GlcNAcylation reduced HA production whereas increased O-GlcNAcylation augmented HA secretion. Additionally, O-GlcNAcylation regulates HAS2 gene expression resulting in accumulation of its mRNA after induction of O-GlcNAcylation with glucosamine treatments. The oxidized LDLs, the most common molecules related to atherosclerosis outcome and progression, are also able to induce a strong HA synthesis when they are in contact with vascular cells. In this review, we present recent described mechanisms involved in HA synthesis regulation and their role in atherosclerosis outcome and development.

1. Introduction

Cardiovascular diseases, which include heart attacks, strokes, and peripheral vascular disease, are the first cause of death in Asia, Europe, and United States [1]. Atherosclerosis is the underlying cause of such vascular disorders, and even though its pathogenesis has been actively investigated in the last decades, several aspects are still elusive. Among the factors involved in plaque formation and progression as well as in vessel thickening (i.e., neointima formation after vascular surgery such as angioplasty or stent placement), extracellular matrix (ECM) plays a pivotal role [2]. ECM composition modifies the behavior of different cell types, including the vascular cells. In fact, the cell microenvironment is involved in most diseases by altering several cell functions. Furthermore, several factors influence the ECM architecture promoting endothelial dysfunction [3, 4].

Arteries consist of three layers, known also as tunica, named intima, media, and adventitia, whose architecture differs in cell population and ECM composition. The intima layer, which is in contact with the bloodstream, is mainly composed of endothelial cells (ECs) attached to the basement membrane. The media are composed of smooth muscle cells (SMCs) producing elastin and small amounts of ECM. The adventitia, the outermost layer, is made by a sheath of fibroblasts with a dense ECM.

Atherosclerotic lesions consist of asymmetric intima thickenings due to a chronic inflammatory response of the arterial wall, initiated by injury caused by hyperglycemia, modified low-density lipoprotein (LDL), or hypertension [5]. The earliest changes that lead to formation of atherosclerotic lesions are due to EC dysfunction [3] and include lowered production of nitric oxide or augmented lipoprotein permeability, immune cell adhesion (by increased ICAM and VCAM), and thrombotic potential [6]. The recruitment of monocytes, which differentiate into macrophages in the intima, is the signal for the secretion of proinflammatory chemokines, including IL-1beta and TNF alpha. Moreover, activated macrophages produce reactive oxygen species that cause LDL oxidation. In fact, when LDL particles become trapped in the vessel wall, they undergo progressive oxidation, and they can be internalized by macrophages through scavenger receptors, which are not regulated and lead to the formation of foam cells [7].

The next stage is fatty streak formation, which initially consists of lipid-laden monocytes and macrophages that are engorged with oxidized LDL (oxLDL) forming foam cells together with T lymphocytes. Subsequently, SMC migration from media to fatty streak increases the number of cells in this area [6]. Thus, in the center of atheromatous plaque, foam cells and extracellular lipid droplets form a core region that is surrounded by a cap of SMCs and a collagen-rich matrix [6, 8].

These events drive to a structural reorganization of ECM and as consequence have a crucial role in altered cellular behavior. In the media portion of vascular wall, the ECM in healthy conditions consists largely of type I and type III fibrillar collagens and elastin, whereas in atherosclerotic lesions it consists mainly of proteoglycans (PGs), such as versican and HA, intermixed with loosely scattered collagen fibrils [9]. PGs represent a special class of glycoproteins that are heavily glycosylated by one or more covalently attached glycosaminoglycan (GAG) chains. These GAG chains are long, linear carbohydrate polymers that are negatively charged under physiological conditions, due to the occurrence of O-sulfation, N-sulfation, and glucuronic/iduronic acid groups. On the other hand, HA, made of the glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc) disaccharide repeats, is the unique GAG and is not covalently linked to core proteins and not sulfated or epimerized. HA synthesis is catalyzed by three HA synthases (HAS) located on the plasma membrane [1012]. HA synthesis, therefore, differs completely from that of the other GAGs, which is a typical process localized in the Golgi. HA synthesis is finely regulated by cytokines, growth factors, and prostaglandins, as well as by the precursor availability (i.e., UDP-GlcNAc and UDP-GlcUA), which modulates HAS gene expression [13, 14]. While collagen inhibits cell growth, PGs and HA stimulate SMC proliferation and migration contributing to vessel wall thickening [1517]. How ECM can modulate cell growth and motility is only partially known. However, PGs can form highly hydrated ECMs that facilitate migration and diffusion of mitogenic molecules, growth factors, and inflammatory mediators. Moreover, ECM remodeling can release active fragments, known as matrikines, of other signaling compounds bound to PGs and GAGs that easily can reach cell surface receptors [18]. Additionally, HA can interact with several cell surface receptors, including CD44, RHAMM, and TLR2/4 that are largely distributed on different cell types, which can trigger internal cell signaling and modulate differentiation, proliferation, migration, and development [19, 20].

In addition to this complex picture, low molecular mass HA can be produced during inflammation due to oxidative stresses, enzymatic degradation by hyaluronidases, and/or aberrations during the HA synthetic process [17]. Interestingly, it was shown that HA synthesis can be induced in ECs by the action of IL-15 in an inflammation model [21]. Although high molecular mass HA exerts antiproliferative, anti-inflammatory, and protective properties on cells, low molecular mass HA has the surprising ability to activate Toll-like receptor (TLR) 2/4 signaling leading to enhancement cell replication, MMP secretion, and invasive properties [11, 20, 22]. In inflammatory responses, the important role of HA receptors in transition of monocytes to macrophages has been reported [11, 2326].

This review will describe the known strategies that vascular cells adopt to regulate HA synthesis, which could identify future targets for pharmacological treatments in vascular pathologies.

2. HA Regulation in ECs

ECs are the most inner lining in blood vessels that control transport of nutrients and other substances from the bloodstream into the tissues. Moreover, the endothelium regulates vascular SMC tone, blood clotting, and angiogenesis. ECs also have a critical role in the inflammation mediating the adhesion and the extravasation of immune cells. Typical endothelial proteins like ICAM-1, P-selectin, and VCAM-1 are key molecules in adhesiveness of circulating cells.

Glycocalyx, a complex network of membrane-bound PGs, glycoproteins, and HA that luminally covers the endothelium, is the real interface between cells and bloodstream. Many cellular properties depend on the glycocalyx composition and integrity [27]. HA in the glycocalyx has a protective role against platelet adhesion and immune cell-EC interactions and therefore fulfills an antithrombotic and anti-inflammatory role [2830]. As a proof of concept Nagy et al. [31] demonstrated damage of the glycocalyx after treatment with 4-methylumbelliferone (a well-known HA synthesis inhibitor [32]), EC dysfunction, increased macrophage driven plaque inflammation, and increased atherosclerosis.

The basal membrane produced by ECs in healthy vessels is mainly composed by collagen IV and laminin. In the early stage of the progression of atherosclerosis, which means before the monocytes are recruited, the inflammatory condition changes the basal membrane into a transitional matrix, which contains fibronectin and fibrinogen [33]. Such a switch alters EC response to flow and shear stress and induces NF-κB activating integrins. As a consequence, the new integrin binding to the inflammatory ECM changes gene expression and enhances endothelial permeability [34].

HA synthesis has been found to be inducible in EC cultures, and its synthesis is triggered by proinflammatory mediators such as IL-1β, IL15, TNF-α, and lipopolysaccharide [35]. The increased secretion of HA during inflammation is due to the overexpression of the isoenzyme HAS2 [21, 36]. The cellular pathway that leads to HAS2 expression involves a NF-κB pathway. Increased HA, together with an augment of the typical adhesion molecules, is responsible for the increased binding of immune cells to ECs and is critical for regulating tissue inflammation. Interestingly, CD44 is also overexpressed in ECs treated with proinflammatory mediators, suggesting a particular model of EC/immune cell interaction. In this model, newly synthesized HA would be kept above the endothelium by CD44, and leukocytes would be bound to HA through their own CD44 [37]. Thus, this model highlights the importance of HA synthesis and confirms the critical role of HAS2 in triggering HA synthesis after proinflammatory signal treatments. Figure 1 summarizes the concepts expressed in this paragraph. Together with the alteration of the basal membrane, HA deposition seems therefore to be the earliest signal of the onset of a vascular disease.

3. HA Synthesis Regulation in Vascular Smooth Muscle Cells

Vessel wall ECM is mainly synthesized by SMCs in the media. Different from EC, vascular SMC (VSMC) cultures produce large amounts of HA that can be easily found in the conditioned medium as well as in the VSMC pericellular space. High expression of HAS2 and HAS3 is necessary for HA synthesis in VSMCs as well as the presence of the enzymes for production of substrates via the UDP-glucose dehydrogenase and hexosamine biosynthetic pathway (HBP) [36, 3941]. From a metabolic point of view, the entering of nutrients in anabolic pathways is a very finely tuned process as all the cellular energetic requirements should be satisfied before biosynthesis of HA is allowed [19]. As the synthesis of HA sugar nucleotide precursors is a high energetic demanding process, we found that adenosine monophosphate activated protein kinase (AMPK) deeply affects HA synthesis [38].

AMPK has a pivotal role in regulating energy homeostasis in eukaryotic cells. In response to a decrease in cellular ATP levels, AMPK reduces the rate of anabolic pathways (ATP-utilizing) and increases the rate of catabolic pathways (ATP-producing) [42]. Through the capacity to detect the ATP : AMP ratio, AMPK acts as a metabolic master switch and phosphorylates key target proteins that control flux through metabolic pathways in order to maintain energy homeostasis. HAS2 is a substrate of AMPK, which phosphorylates threonine 110 to inhibit HAS2 enzymatic activity [38]. Interestingly, AMPK does not alter the synthesis of other GAGs secreted by VSMCs, highlighting the specificity of AMPK action on HA synthesis. This aspect could explain the vasoprotective effect of AMPK activation, obtained also by the antidiabetic drug metformin, to reduce neointima formation in animal models for atherosclerosis [43] (Figure 2).

Glucose is a major cell substrate, and its utilization is finely regulated allosterically as well as hormonally. HBP represents an alternative glucose pathway in the cells which leads to the formation of the crucial sugar nucleotide UDP-GlcNAc [44]. Besides being a substrate for HA and other glycoconjugate biosyntheses, UDP-GlcNAc is the substrate of O-GlcNAc transferase (OGT), the critical enzyme for protein O-GlcNAcylation [45], which is the reversible modification of nuclear or cytosolic proteins by attachment of a single β-GlcNAc moiety by O-linkage to specific serine/threonine residues. O-GlcNAcylation increased typically in hyperglycemic conditions, due to the entering of the excess of glucose in the HBP, and is involved in several diabetic complications [4648]. As angiopathies are one of the main complications of diabetes and HA is altered in human diabetic patients [49] as well as in animal models of this pathology [50], it is not surprising that HA synthesis is induced by HAS2 O-GlcNAcylation (Figure 3) [39].

O-GlcNAcylation of HAS2 occurs on serine 221 in the cytoplasmic loop, which stabilizes the enzyme in plasma and cytosolic membranes. This allows the enzyme to have a half-life of more than 5 hours before proteasomal degradation (although in other cell types HAS2 is ubiquitinated [51]). In contrast, HAS2 without this modification only has a half-life of 17 minutes [39].

O-GlcNAcylation is also able to modulate gene expression, and in VSMCs this glycosylation leads to an increment of HAS2 mRNA [52]. The molecular mechanism of such regulation is complex and does not involve the typical O-GlcNAcylated transcription factors that are known to regulate HA synthesis like YY1 and SP1, which are able to interact with the HAS2 promoter [13]. By using ChIP analyses from mice with high O-GlcNAcylation levels, we found a significant signal in correspondence with the natural antisense transcript for HAS2 (HAS2-AS1), which is a particular long noncoding RNA transcribed using the opposite strand of HAS2 locus on chromosome 8 [53]. HAS2 and HAS2-AS1 RNA molecules share about 200 base pairs and can form a RNA:RNA duplex. In previous papers antisense transcripts have been described to stabilize their sense mRNA [54, 55], but this mechanism did not work with VSMCs. In contrast, we found that HAS2-AS1 transcription is initiated by O-GlcNAcylation of RelA (a component of NF-κB complex) [56], and HAS2-AS1 was necessary to change chromatin structure around the HAS2 promoter to allow more efficient binding of RNA polymerase 2, thereby enhancing HAS2 gene expression (Figure 4) [52]. In vivo analyses confirmed the crucial role of HAS2-AS1 in the regulation of HAS2 in humans and in animal models for vascular pathologies [52]. Although investigations are still in progress, our hypothesis is that HAS2-AS1 could alter the epigenetic signature of the HAS2 promoter by switching it into a more active chromatin. The more recent theories about the long noncoding RNA functions highlight their role in recruiting enzymes able to modify histones and DNA in particular loci of the genome [5760].

4. LDL and HA Metabolism

Despite the great challenge to discover specific markers for the onset of atherosclerosis, at the moment the unique factors routinely evaluated in the clinical practice are the quantification of circulating LDL-cholesterol and the ratio LDL/HDL. The presence within the intima of cholesterol-rich macromolecules induces the formation of foam cells, originating from both macrophages and SMCs [6, 61] encircled by altered ECM. As recently reported, upon activation with the endotoxin LPS, macrophages undergo activation to the M1 phenotype [62] with a concomitant rapid increase in Has1 mRNA and inhibition of hyaluronidases 1 and 2, the major HA degrading enzymes. Nevertheless, HA deposition could only be detected after inhibiting lysosomal and endosomal activities with chloroquine, indicating a rapid turnover and degradation of HA from the ECM [63]. These results are in line with the increasing evidence of the pivotal role of SMCs as ECM modulators. When SMCs resident in the tunica intima and media [64] get in contact with chemically modified LDL, they produce the inflammatory ECM of the plaques. Given the numerous oxidative events associated with the development of an inflammatory atherosclerotic plaque, LDLs, which are accumulated early in the intima primarily from enhanced retention by the GAGs, are converted into oxLDL or into aggregate LDL (aggLDL). Oxidation is the most representative modification, and several enzymatic and nonenzymatic oxidant candidates have been described to be involved [65]. Oxidation may affect both lipid and protein moieties of the particles, and as a result, a series of biologically active species including peroxides, aldehydes, and oxysterols may be produced [66, 67]. The two different modifications of LDL exert different roles in VSMCs. Only oxLDL induced the neosynthesis and deposition of HA, while aggLDL engulfed the cells with lipids without affecting the ECM.

Several scavenger receptors have been reported to be able to internalize oxLDL (e.g., SR-PSOX, SR-AI, CD36, LOX-1, and LRP1). However, even though some of them are present on the SMC membrane, only LOX-1 was upregulated after oxLDL exposure [68, 69]. The oxLDL entrance via LOX-1 has various effects inside the cells: upregulation of LOX-1, increasing the load of lipids and ROS in ER leading to ER stress, and overexpression of HAS2 and HAS3 with concomitant deposition of HA in the ECM (Figure 5), all of which occur during atherosclerosis progression. The increase in HA in the SMC ECM promotes macrophage adhesion and activation as well as their higher migration ability.

LOX-1 is a well-known receptor expressed by vascular ECs, where LOX-1 mediates oxLDL-induced EC apoptosis via an elevation of intracellular NADPH oxidase, which in turn activates the ER stress pathway [70]. However, remarkably, there is no information given for HA metabolism.

The ER stress rescue (also named UPR, unfolded protein response) mechanism is induced in both SMCs and ECs after oxLDL loading, including the expression of several proteins, including CHOP and GRP78, that can modify the activity of transcription factors in the cell nucleus [71]. This intriguing mechanism has been taken into consideration in the investigation of several ECM molecules, including HA [72, 73]. Given the role of LDL in cholesterol metabolism, a key factor in this context is the LXR/RXR sterol sensor system [74]. Liver X receptors (LXR) of the nuclear receptor superfamily are factors that regulate the transcription of several genes involved in cholesterol metabolism. It is noteworthy that the use of cholesterol depleted ox-LDL fails to stimulate HAS2 overexpression and HA synthesis. Interestingly HAS3 was upregulated by these macromolecules; moreover, cholesterol and oxysterols control the expression of HAS3 while only oxysterols can regulate HAS2 transcript levels [69]. It seems therefore evident that a different control of the two enzymes HAS2 and HAS3, regulated by oxysterols/LXR/RXR and/or UPR factors, can reflect their different role in cell behavior.

5. Conclusions

Vessel wall ECM components have a great impact on cell behaviour and, therefore, on vascular pathologies. The critical effect of HA was demonstrated in different ways, and a better knowledge of the mechanisms that control HAS expression could identify future targets for pharmacological treatments of circulatory diseases.


ECM:Extracellular matrix
MMP:Matrix metalloprotease
ECs:Endothelial cells
SMCs:Smooth muscle cells
UDP-GlcNAc:Uridine diphosphate-N-acetylglucosamine
HAS:Hyaluronan synthase
AMPK:Adenosine monophosphate activated protein kinase
HBP:Hexosamine biosynthetic pathway
oxLDL:Oxidized low-density lipoproteins.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This work was supported by FAR, PRIN, and EU grant IRSES INFLAMA to Alberto Passi. The authors acknowledge the Ph.D. School in Biological and Medical Sciences for Maria Luisa D’Angelo and Ilaria Caon fellowships.


  1. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics—2012 update: a report from the American Heart Association,” Circulation, vol. 125, no. 1, pp. e2–e220, 2012. View at: Publisher Site | Google Scholar
  2. P. M. Vanhoutte, “Endothelial dysfunction—the first step toward coronary arteriosclerosis,” Circulation Journal, vol. 73, no. 4, pp. 595–601, 2009. View at: Publisher Site | Google Scholar
  3. M. J. Merrilees, B. W. Beaumont, K. R. Braun et al., “Neointima formed by arterial smooth muscle cells expressing versican variant V3 is resistant to lipid and macrophage accumulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 6, pp. 1309–1316, 2011. View at: Publisher Site | Google Scholar
  4. B. Messner and D. Bernhard, “Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 3, pp. 509–515, 2014. View at: Publisher Site | Google Scholar
  5. L. Badimon and G. Vilahur, “LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos,” Annals of the New York Academy of Sciences, vol. 1254, no. 1, pp. 18–32, 2012. View at: Publisher Site | Google Scholar
  6. J. X. Rong, M. Shapiro, E. Trogan, and E. A. Fisher, “Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13531–13536, 2003. View at: Publisher Site | Google Scholar
  7. J. G. Dickhout, Š. Lhoták, B. A. Hilditch et al., “Induction of the unfolded protein response after monocyte to macrophage differentiation augments cell survival in early atherosclerotic lesions,” The FASEB Journal, vol. 25, no. 2, pp. 576–589, 2011. View at: Publisher Site | Google Scholar
  8. D. Vigetti, P. Moretto, M. Viola et al., “Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging,” The FASEB Journal, vol. 20, no. 8, pp. 1118–1130, 2006. View at: Publisher Site | Google Scholar
  9. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at: Publisher Site | Google Scholar
  10. D. Jiang, J. Liang, and P. W. Noble, “Hyaluronan in tissue injury and repair,” Annual Review of Cell and Developmental Biology, vol. 23, pp. 435–461, 2007. View at: Publisher Site | Google Scholar
  11. D. Jiang, J. Liang, and P. W. Noble, “Hyaluronan as an immune regulator in human diseases,” Physiological Reviews, vol. 91, no. 1, pp. 221–264, 2011. View at: Publisher Site | Google Scholar
  12. E. G. Karousou, M. Viola, A. Genasetti et al., “Application of polyacrylamide gel electrophoresis of fluorophore-labeled saccharides for analysis of hyaluronan and chondroitin sulfate in human and animal tissues and cell cultures,” Biomedical Chromatography, vol. 19, no. 10, pp. 761–765, 2005. View at: Publisher Site | Google Scholar
  13. R. H. Tammi, A. G. Passi, K. Rilla et al., “Transcriptional and post-translational regulation of hyaluronan synthesis,” FEBS Journal, vol. 278, no. 9, pp. 1419–1428, 2011. View at: Publisher Site | Google Scholar
  14. D. Vigetti, M. Viola, E. Karousou, G. de Luca, and A. Passi, “Metabolic control of hyaluronan synthases,” Matrix Biology, vol. 35, pp. 8–13, 2014. View at: Publisher Site | Google Scholar
  15. S. P. Evanko, J. C. Angello, and T. N. Wight, “Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 4, pp. 1004–1013, 1999. View at: Publisher Site | Google Scholar
  16. D. Vigetti, M. Viola, E. Karousou et al., “Hyaluronan-CD44-ERK1/2 regulate human aortic smooth muscle cell motility during aging,” The Journal of Biological Chemistry, vol. 283, no. 7, pp. 4448–4458, 2008. View at: Publisher Site | Google Scholar
  17. D. Kothapalli, L. Zhao, E. A. Hawthorne et al., “Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells,” The Journal of Cell Biology, vol. 176, no. 4, pp. 535–544, 2007. View at: Publisher Site | Google Scholar
  18. J. C. Monboisse, J. B. Oudart, L. Ramont, S. Brassart-Pasco, and F. X. Maquart, “Matrikines from basement membrane collagens: a new anti-cancer strategy,” Biochimica et Biophysica Acta, vol. 1840, no. 8, pp. 2589–2598, 2014. View at: Publisher Site | Google Scholar
  19. D. Vigetti, E. Karousou, M. Viola, S. Deleonibus, G. de Luca, and A. Passi, “Hyaluronan: biosynthesis and signaling,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1840, no. 8, pp. 2452–2459, 2014. View at: Publisher Site | Google Scholar
  20. M. Nardini, M. Ori, D. Vigetti, R. Gornati, I. Nardi, and R. Perris, “Regulated gene expression of hyaluronan synthases during Xenopus laevis development,” Gene Expression Patterns, vol. 4, no. 3, pp. 303–308, 2004. View at: Publisher Site | Google Scholar
  21. P. Estess, A. Nandi, M. Mohamadzadeh, and M. H. Siegelman, “Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-dependent pathway in vivo,” The Journal of Experimental Medicine, vol. 190, no. 1, pp. 9–19, 1999. View at: Publisher Site | Google Scholar
  22. D. Vigetti and A. Passi, “Hyaluronan synthases posttranslational regulation in cancer,” in Advances in Cancer Research, vol. 123, pp. 95–119, Elsevier, 2014. View at: Publisher Site | Google Scholar
  23. M. Afanasyeva, D. Georgakopoulos, D. F. Belardi et al., “Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation with cardiac function,” The American Journal of Pathology, vol. 164, no. 3, pp. 807–815, 2004. View at: Google Scholar
  24. K. L. Brown, A. Maiti, and P. Johnson, “Role of sulfation in CD44-mediated hyaluronan binding induced by inflammatory mediators in human CD14+ peripheral blood monocytes,” Journal of Immunology, vol. 167, no. 9, pp. 5367–5374, 2001. View at: Publisher Site | Google Scholar
  25. S. Shahrara, C. C. Park, V. Temkin, J. W. Jarvis, M. V. Volin, and R. M. Pope, “RANTES modulates TLR4-induced cytokine secretion in human peripheral blood monocytes,” Journal of Immunology, vol. 177, no. 8, pp. 5077–5087, 2006. View at: Publisher Site | Google Scholar
  26. C. Termeer, F. Benedix, J. Sleeman et al., “Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4,” Journal of Experimental Medicine, vol. 195, no. 1, pp. 99–111, 2002. View at: Publisher Site | Google Scholar
  27. S. Reitsma, D. W. Slaaf, H. Vink, M. A. M. J. van Zandvoort, and M. G. A. Oude Egbrink, “The endothelial glycocalyx: composition, functions, and visualization,” Pflugers Archiv European Journal of Physiology, vol. 454, no. 3, pp. 345–359, 2007. View at: Publisher Site | Google Scholar
  28. B. M. van den Berg, H. Vink, and J. A. E. Spaan, “The endothelial glycocalyx protects against myocardial edema,” Circulation Research, vol. 92, no. 6, pp. 592–594, 2003. View at: Publisher Site | Google Scholar
  29. A. A. Constantinescu, H. Vink, and J. A. E. Spaan, “Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 9, pp. 1541–1547, 2003. View at: Publisher Site | Google Scholar
  30. H. Vink, A. A. Constantinescu, and J. A. E. Spaan, “Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion,” Circulation, vol. 101, no. 13, pp. 1500–1502, 2000. View at: Publisher Site | Google Scholar
  31. N. Nagy, T. Freudenberger, A. Melchior-Becker et al., “Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis,” Circulation, vol. 122, no. 22, pp. 2313–2322, 2010. View at: Publisher Site | Google Scholar
  32. T. Nakamura, K. Takagaki, S. Shibata, K. Tanaka, T. Higuchi, and M. Endo, “Hyaluronic-acid-deficient extracellular matrix induced by addition of 4-methylumbelliferone to the medium of cultured human skin fibroblasts,” Biochemical and Biophysical Research Communications, vol. 208, no. 2, pp. 470–475, 1995. View at: Publisher Site | Google Scholar
  33. A. W. Orr, J. M. Sanders, M. Bevard, E. Coleman, I. J. Sarembock, and M. A. Schwartz, “The subendothelial extracellular matrix modulates NF-kappaB activation by flow: a potential role in atherosclerosis,” Journal of Cell Biology, vol. 169, no. 1, pp. 191–202, 2005. View at: Publisher Site | Google Scholar
  34. A. W. Orr, R. Stockton, M. B. Simmers et al., “Matrix-specific p21-activated kinase activation regulates vascular permeability in atherogenesis,” Journal of Cell Biology, vol. 176, no. 5, pp. 719–727, 2007. View at: Publisher Site | Google Scholar
  35. A. Genasetti, D. Vigetti, M. Viola et al., “Hyaluronan and human endothelial cell behavior,” Connective Tissue Research, vol. 49, no. 3-4, pp. 120–123, 2008. View at: Publisher Site | Google Scholar
  36. D. Vigetti, A. Genasetti, E. Karousou et al., “Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-κB (NF-κB) pathway,” The Journal of Biological Chemistry, vol. 285, no. 32, pp. 24639–24645, 2010. View at: Publisher Site | Google Scholar
  37. B. Ruffell and P. Johnson, “The regulation and function of hyaluronan binding by CD44 in the immune system,” 2009. View at: Google Scholar
  38. D. Vigetti, M. Clerici, S. Deleonibus et al., “Hyaluronan synthesis is inhibited by adenosine monophosphate-activated protein kinase through the regulation of HAS2 activity in human aortic smooth muscle cells,” Journal of Biological Chemistry, vol. 286, no. 10, pp. 7917–7924, 2011. View at: Publisher Site | Google Scholar
  39. D. Vigetti, S. Deleonibus, P. Moretto et al., “Role of UDP-N-acetylglucosamine (GlcNAc) and O-GlcNacylation of hyaluronan synthase 2 in the control of chondroitin sulfate and hyaluronan synthesis,” The Journal of Biological Chemistry, vol. 287, no. 42, pp. 35544–35555, 2012. View at: Publisher Site | Google Scholar
  40. D. Vigetti, M. Ori, M. Viola et al., “Molecular cloning and characterization of UDP-glucose dehydrogenase from the amphibian Xenopus laevis and its involvement in hyaluronan synthesis,” Journal of Biological Chemistry, vol. 281, no. 12, pp. 8254–8263, 2006. View at: Publisher Site | Google Scholar
  41. D. Vigetti, M. Rizzi, M. Viola et al., “The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells,” Glycobiology, vol. 19, no. 5, pp. 537–546, 2009. View at: Publisher Site | Google Scholar
  42. H. D. Grahame, “AMPK: a target for drugs and natural products with effects on both diabetes and cancer,” Diabetes, vol. 62, no. 7, pp. 2164–2172, 2013. View at: Publisher Site | Google Scholar
  43. I. Pernicova and M. Korbonits, “Metformin—mode of action and clinical implications for diabetes and cancer,” Nature Reviews Endocrinology, vol. 10, no. 3, pp. 143–156, 2014. View at: Publisher Site | Google Scholar
  44. C. Butkinaree, K. Park, and G. W. Hart, “O-linked β-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1800, no. 2, pp. 96–106, 2010. View at: Publisher Site | Google Scholar
  45. G. W. Hart, M. P. Housley, and C. Slawson, “Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins,” Nature, vol. 446, no. 7139, pp. 1017–1022, 2007. View at: Publisher Site | Google Scholar
  46. M. G. Buse, “Hexosamines, insulin resistance, and the complications of diabetes: current status,” American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 1, pp. E1–E8, 2006. View at: Publisher Site | Google Scholar
  47. B. Laczy, B. G. Hill, K. Wang et al., “Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 1, pp. H13–H28, 2009. View at: Publisher Site | Google Scholar
  48. J. Nigro, N. Osman, A. M. Dart, and P. J. Little, “Insulin resistance and atherosclerosis,” Endocrine Reviews, vol. 27, no. 3, pp. 242–259, 2006. View at: Publisher Site | Google Scholar
  49. L. Heickendorff, T. Ledet, and L. M. Rasmussen, “Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque,” Diabetologia, vol. 37, no. 3, pp. 286–292, 1994. View at: Publisher Site | Google Scholar
  50. T. O. McDonald, R. G. Gerrity, C. Jen et al., “Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis,” Journal of Histochemistry and Cytochemistry, vol. 55, no. 11, pp. 1149–1157, 2007. View at: Publisher Site | Google Scholar
  51. E. Karousou, M. Kamiryo, S. S. Skandalis et al., “The activity of hyaluronan synthase 2 is regulated by dimerization and ubiquitination,” The Journal of Biological Chemistry, vol. 285, no. 31, pp. 23647–23654, 2010. View at: Publisher Site | Google Scholar
  52. D. Vigetti, S. Deleonibus, P. Moretto et al., “Natural antisense transcript for hyaluronan synthase 2 (HAS2-AS1) induces transcription of HAS2 via protein O-GlcNAcylation,” The Journal of Biological Chemistry, vol. 289, no. 42, pp. 28816–28826, 2014. View at: Publisher Site | Google Scholar
  53. H. Chao and A. P. Spicer, “Natural antisense mRNAs to hyaluronan synthase 2 inhibit hyaluronan biosynthesis and cell proliferation,” The Journal of Biological Chemistry, vol. 280, no. 30, pp. 27513–27522, 2005. View at: Publisher Site | Google Scholar
  54. D. R. Michael, A. O. Phillips, A. Krupa et al., “The human hyaluronan synthase 2 (HAS2) gene and its natural antisense RNA exhibit coordinated expression in the renal proximal tubular epithelial cell,” The Journal of Biological Chemistry, vol. 286, no. 22, pp. 19523–19532, 2011. View at: Publisher Site | Google Scholar
  55. M. A. Faghihi, F. Modarresi, A. M. Khalil et al., “Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase,” Nature Medicine, vol. 14, no. 7, pp. 723–730, 2008. View at: Publisher Site | Google Scholar
  56. D. F. Allison, J. J. Wamsley, M. Kumar et al., “Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NF-κB acetylation and transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, pp. 16888–16893, 2012. View at: Publisher Site | Google Scholar
  57. D. Vigetti, M. Viola, E. Karousou et al., “Epigenetics in extracellular matrix remodeling and hyaluronan metabolism,” FEBS Journal, vol. 281, no. 22, pp. 4980–4992, 2014. View at: Publisher Site | Google Scholar
  58. T. R. Mercer and J. S. Mattick, “Structure and function of long noncoding RNAs in epigenetic regulation,” Nature Structural and Molecular Biology, vol. 20, no. 3, pp. 300–307, 2013. View at: Publisher Site | Google Scholar
  59. M. Magistri, M. A. Faghihi, G. St Laurent, and C. Wahlestedt, “Regulation of chromatin structure by long noncoding RNAs: focus on natural antisense transcripts,” Trends in Genetics, vol. 28, no. 8, pp. 389–396, 2012. View at: Publisher Site | Google Scholar
  60. J. T. Lee, “Epigenetic regulation by long noncoding RNAs,” Science, vol. 338, no. 6113, pp. 1435–1439, 2012. View at: Publisher Site | Google Scholar
  61. A. C. Doran, N. Meller, and C. A. McNamara, “Role of smooth muscle cells in the initiation and early progression of atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 812–819, 2008. View at: Publisher Site | Google Scholar
  62. A. Sica and A. Mantovani, “Macrophage plasticity and polarization: in vivo veritas,” The Journal of Clinical Investigation, vol. 122, no. 3, pp. 787–795, 2012. View at: Publisher Site | Google Scholar
  63. M. Y. Chang, Y. Tanino, V. Vidova et al., “Reprint of: a rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease,” Matrix Biology, vol. 35, pp. 162–173, 2014. View at: Publisher Site | Google Scholar
  64. P. Libby, P. M. Ridker, and G. K. Hansson, “Progress and challenges in translating the biology of atherosclerosis,” Nature, vol. 473, no. 7347, pp. 317–325, 2011. View at: Publisher Site | Google Scholar
  65. R. Stocker and J. F. Keaney Jr., “Role of oxidative modifications in atherosclerosis,” Physiological Reviews, vol. 84, no. 4, pp. 1381–1478, 2004. View at: Publisher Site | Google Scholar
  66. T. Hevonoja, M. O. Pentikäinen, M. T. Hyvönen, P. T. Kovanen, and M. Ala-Korpela, “Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL,” Biochimica et Biophysica Acta, vol. 1488, no. 3, pp. 189–210, 2000. View at: Publisher Site | Google Scholar
  67. H. Yoshida and R. Kisugi, “Mechanisms of LDL oxidation,” Clinica Chimica Acta, vol. 411, no. 23-24, pp. 1875–1882, 2010. View at: Publisher Site | Google Scholar
  68. S. Mitra, T. Goyal, and J. L. Mehta, “Oxidized LDL, LOX-1 and atherosclerosis,” Cardiovascular Drugs and Therapy, vol. 25, no. 5, pp. 419–429, 2011. View at: Publisher Site | Google Scholar
  69. M. Viola, B. Bartolini, D. Vigetti et al., “Oxidized low density lipoprotein (LDL) affects hyaluronan synthesis in human aortic smooth muscle cells,” The Journal of Biological Chemistry, vol. 288, no. 41, pp. 29595–29603, 2013. View at: Publisher Site | Google Scholar
  70. D. Hong, Y.-P. Bai, H.-C. Gao et al., “Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway,” Atherosclerosis, vol. 235, no. 2, pp. 310–317, 2014. View at: Publisher Site | Google Scholar
  71. I. Tabas and D. Ron, “Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress,” Nature Cell Biology, vol. 13, no. 3, pp. 184–190, 2011. View at: Publisher Site | Google Scholar
  72. D. Vigetti, A. Genasetti, E. Karousou et al., “Modulation of hyaluronan synthase activity in cellular membrane fractions,” The Journal of Biological Chemistry, vol. 284, no. 44, pp. 30684–30694, 2009. View at: Publisher Site | Google Scholar
  73. D. Vigetti, E. Karousou, M. Viola, and A. Passi, “Analysis of hyaluronan synthase activity,” in Glycosaminoglycans, vol. 1229 of Methods in Molecular Biology, pp. 201–208, Springer, New York, NY, USA, 2015. View at: Publisher Site | Google Scholar
  74. A. C. Calkin and P. Tontonoz, “Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR,” Nature Reviews Molecular Cell Biology, vol. 13, no. 4, pp. 213–224, 2012. View at: Publisher Site | Google Scholar

Copyright © 2015 Manuela Viola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.